Evidence map›Paper›PMID 26225425›Full record

ArticlePloS one2015

All-Trans Retinoic Acid Induces TGF-β2 in Intestinal Epithelial Cells via RhoA- and p38α MAPK-Mediated Activation of the Transcription Factor ATF2.

Kopperuncholan Namachivayam, Krishnan MohanKumar, Dima Arbach, Ramasamy Jagadeeswaran, Sunil K Jain, Viswanathan Natarajan, Dolly Mehta, Robert P Jankov, Akhil Maheshwari

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed, 1 pooled it
1.7field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed, 1 synthesis or guideline pooled it, 23 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. Article
  5. Review
  6. Review
  7. Review
  8. Review
  9. Article
  10. Article
  11. Review
  12. Article
  13. Article
  14. Review
  15. SPOP promotes ATF2 ubiquitination and degradation to suppress prostate cancer progression.Journal of experimental & clinical cancer research : CR · 2018
    Article
  16. Article
  17. Levels and effectiveness of oral retinol supplementation in VLBW preterm infants.International journal of immunopathology and pharmacology
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 4 institutions in 2 countries.

Kopperuncholan NamachivayamDepartment of Pediatrics, University of Illinois at Chicago, Chicago, Illinois, United States of America; Department of Pediatrics, Morsani College of Medicine, University of South Florida, Tampa, Florida, United States of America.
Krishnan MohanKumarDepartment of Pediatrics, University of Illinois at Chicago, Chicago, Illinois, United States of America; Department of Pediatrics, Morsani College of Medicine, University of South Florida, Tampa, Florida, United States of America.
Dima ArbachDepartment of Pediatrics, University of Illinois at Chicago, Chicago, Illinois, United States of America.
Ramasamy JagadeeswaranDepartment of Pediatrics, University of Illinois at Chicago, Chicago, Illinois, United States of America.
Sunil K JainDepartment of Pediatrics, University of Texas Medical Branch, Galveston, Texas, United States of America.
Viswanathan NatarajanDepartment of Pharmacology, University of Illinois at Chicago, Chicago, Illinois, United States of America.
Dolly MehtaDepartment of Pharmacology, University of Illinois at Chicago, Chicago, Illinois, United States of America.
Robert P JankovPhysiology & Experimental Medicine Program, Hospital for Sick Children Research Institute, Toronto, Ontario, Canada; Department of Physiology, University of Toronto, Toronto, Ontario, Canada; Department of Pediatrics, University of Toronto, Toronto, Ontario, Canada.
Akhil MaheshwariDepartment of Pediatrics, University of Illinois at Chicago, Chicago, Illinois, United States of America; Department of Pediatrics, Morsani College of Medicine, University of South Florida, Tampa, Florida, United States of America; Department of Pharmacology, University of Illinois at Chicago, Chicago, Illinois, United States of America; Department of Molecular Medicine, Morsani College of Medicine, University of South Florida, Tampa, Florida, United States of America; Department of Community and Family Health, College of Public Health, University of South Florida, Tampa, Florida, United States of America.
University of Illinois Chicago · USHospital for Sick Children · CAThe University of Texas Medical Branch at Galveston · USUniversity of South Florida · US

Funding

Focal Adhesion Kinase Regulation of Lung Vascular Permeability and EdemagenesisR01HL084153 · NHLBI · UNIVERSITY OF ILLINOIS AT CHICAGO · PI MEHTA, DOLLY · 2007 to 2022
$5.4M
Role of Transforming Growth Factor-beta in Neonatal Necrotizing EnterocolitisR01HD059142 · NICHD · UNIVERSITY OF ILLINOIS AT CHICAGO · PI MAHESHWARI, AKHIL · 2009 to 2013
$1.7M
NHLBI NIH HHS R01 HL084153NICHD NIH HHS R01 HD059142NICHD NIH HHS R01HD059142
6 · The paper itself

Abstract

objectiveWe have shown previously that preterm infants are at risk of necrotizing enterocolitis (NEC), an inflammatory bowel necrosis typically seen in infants born prior to 32 weeks' gestation, because of the developmental deficiency of transforming growth factor (TGF)-β2 in the intestine. The present study was designed to investigate all-trans retinoic acid (atRA) as an inducer of TGF-β2 in intestinal epithelial cells (IECs) and to elucidate the involved signaling mechanisms.

methodsAtRA effects on intestinal epithelium were investigated using IEC6 cells. TGF-β2 expression was measured using reverse transcriptase-quantitative polymerase chain reaction (RT-qPCR) and Western blots. Signaling pathways were investigated using Western blots, transiently-transfected/transduced cells, kinase arrays, chromatin immunoprecipitation, and selective small molecule inhibitors.

resultsAtRA-treatment of IEC6 cells selectively increased TGF-β2 mRNA and protein expression in a time- and dose-dependent fashion, and increased the activity of the TGF-β2 promoter. AtRA effects were mediated via RhoA GTPase, Rho-associated, coiled-coil-containing protein kinase 1 (ROCK1), p38α MAPK, and activating transcription factor (ATF)-2. AtRA increased phospho-ATF2 binding to the TGF-β2 promoter and increased histone H2B acetylation in the TGF-β2 nucleosome, which is typically associated with transcriptional activation.

conclusionsAtRA induces TGF-β2 expression in IECs via RhoA- and p38α MAPK-mediated activation of the transcription factor ATF2. Further studies are needed to investigate the role of atRA as a protective/therapeutic agent in gut mucosal inflammation.

Indexed as

Activating Transcription Factor 2HumansIntestinal MucosaMitogen-Activated Protein Kinase 14PhosphorylationrhoA GTP-Binding ProteinSmad ProteinsTransforming Growth Factor betaTretinoinActivating Transcription Factor 2Mitogen-Activated Protein Kinase 14rhoA GTP-Binding ProteinSmad ProteinsTransforming Growth Factor betaTretinoin

Identifiers

PMID26225425
PMCPMC4520553
OpenAlexW2249070556

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.